SPRY,ARS Pharmaceuticals, Inc. | Healthcare

Healthcare

SPRY

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

ARS Pharmaceuticals, Inc.SPRY

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions.

It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis.

The company was founded in 2015 and is based in San Diego, California.

Latest News >

ChipMOS Technologies Reports 15.4% Increase in August Revenue

Sep 11, 2024

07:00 AM EDT, 09/10/2024 (MT Newswires) -- ChipMOS Technologies ( IMOS ) reported Tuesday revenue of 2.12 billion new Taiwanese dollars ($66.2 million), up 15.4% from a year earlier. Revenue for the month was also 2.5% higher than July revenue. ...

BMW trims 2024 profit margin, deliveries forecast

Sep 11, 2024

(Reuters) - BMW trimmed its guidance for profitability and deliveries on Tuesday, saying it faces headwinds in the automotive segment resulting from delivery stops and technical actions linked to the Integrated Braking System (IBS). The German carmaker expects its earnings before interest and taxes (EBIT) margin to be between 6% and 7% for 2024, having previously guided for the figure...

Infosys Partners With Proximus to Enhance Digital Security

Sep 11, 2024

07:04 AM EDT, 09/10/2024 (MT Newswires) -- Infosys ( INFY ) and Proximus Group said Tuesday they are partnering to provide clients with packaged services to enhance digital security. Financial terms weren't disclosed. Under the deal, the two companies will offer clients products of Proximus' affiliates, including Route Mobile's Communications Platform as a Service and Telesign's Digital Identity solutions, combined...

Chinese EV maker BYD sets higher annual sales target, brokerage report shows

Sep 11, 2024

BEIJING, Sept 10 (Reuters) - Chinese electric automaker BYD aims to sell 4 million vehicles this year, Morgan Stanley ( MS ) said in a report on Monday, suggesting an 11% upward revision to the company's 2024 sales target set earlier this year. The goal would put BYD almost at par with Ford Motor ( F ) which ranked sixth...